• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Medication Management Services Leader Cureatr Acquires SinfoníaRx

    3/3/23 12:06:00 PM ET
    $TRHC
    Business Services
    Consumer Discretionary
    Get the next $TRHC alert in real time by email

    NEW YORK, March 3, 2023 /PRNewswire/ -- Cureatr, a national, value-based medication management services company improving quality and reducing total cost of care, announces it has acquired the SinfoníaRx business, an industry leader in medication therapy management (MTM), from Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications.

    Cureatr is the new breed of clinical provider that uses cutting-edge healthcare data, technology, insights, and patient relationship-building to solve the complex medication management equation.

    This acquisition will round out Cureatr's existing clinical pharmacy services to include MTM and expand the company's scale with a larger team of clinical pharmacists, pharmacy technicians, and pharmacy interns serving health plans, pharmacy benefit managers (PBMs), and patients across the country. With the additional capability to offer MTM services, Cureatr will further its commitment to better manage medications and reduce the total cost of care through longitudinal and targeted clinical service programs. These programs aim to improve patient experience, medication adherence, access, quality, and safety while reducing avoidable utilization and adverse drug outcomes.

    "Cureatr continues its mission to bring a clinical pharmacist to the care team of every patient who needs one and provide the critical services patients need, at the moment they need it, to keep them healthy and reduce risk," said Richard Resnick, Chief Executive Officer of Cureatr. "The addition of the SinfoníaRx team and our ability to provide MTM services further advance our mission. We are thrilled to welcome this accomplished team to Cureatr, honored to provide measurable value to our new customers, and excited to realize the synergies of coming together."

    "Cureatr has demonstrated a tremendously positive impact in the transitions of care space through a truly unique clinical model," said Kevin Boesen, Founder of SinfoníaRx. "We're thrilled to bring this expertise to the millions of patients we serve by integrating Cureatr's unique assets and incredibly talented clinical pharmacists, comprehensive data, and strong technology."

    Cureatr will utilize and continue to invest in SinfoníaRx's state-of-the-art call centers, strong partnerships with pharmacy schools, and proprietary software, RxCompanion. This powerful solution personalizes patient care by alerting for potential medication regimen problems utilizing pharmacy claims, medical claims, and other sources. Based on urgency and complexity, RxCompanion triages patients to the most qualified clinical team member for appropriate intervention and support.

    Cureatr strives to be the vanguard in repairing the $528 billion suboptimal medication management problem in the United States. Together with the SinfoníaRx team and assets onboard, Cureatr will continue pursuing its vision for a world where people needing medications can access and use them safely and effectively to live long, healthy lives.

    Uniquely positioned as the leading provider of holistic, patient-centered, and comprehensive medication management inspired by patients and designed by clinicians, Cureatr Clinic's pharmacists leverage Cureatr's powerful medication management platform (Meds 360°) to reconcile a patient's medications and identify potential health risks from numerous potential sources/causes, among other benefits. Meds 360° aggregates, analyzes, and reports on medical history data from multiple third-party sources, including real-time admission, discharge, and transfer (ADT) notifications, medical progress notes, labs, discharge summaries, and 12-month prescription fill history, complemented with health plan-provided pharmacy and medical claims.

    The Cureatr Clinic's telehealth programs have four foundational pillars: clinical pharmacist expertise, data and technology enablement, member and provider engagement, and evidence-based results. The programs focus on reducing total cost of care, and avoidable utilization, which are differentiated by the company's ability to:

    • Access comprehensive fill data, inclusive of scripts paid for with cash, coupon, and workers' compensation.
    • Maintain a tight grip on clinical quality and positive member experience that may not be as easy to maintain in a delegated third-party call center, a gig-economy staffing model, or through AI-based engagement and intervention models.
    • Follow patients nationally from a discharge notification perspective, which allows for real-time clinical intervention and coordination when patients need support most.
    • Reach and engage patients through omnichannel outreach methods.
    • Scale an in-house, board-certified clinical pharmacist workforce with licensure to work with the entire eligible patient population in any state.
    • Make unbiased recommendations in the best interest of the health plan and member, with no in-house pharmacy or mail order arm with conflicting incentives. Cureatr connects members with existing health plan benefits and programs.

    About Cureatr

    Cureatr is the new breed of clinical, value-based provider: using expert clinical pharmacists, cutting-edge healthcare data, technology, insights, and patient relationship-building to solve the complex medication management equation, ultimately reducing cost of care and improving patient outcomes.

    Cureatr Clinic, a national medication management clinic, is staffed by residency-trained and board-certified clinical pharmacists who work to combat suboptimal medication use, especially during those transitions of care where the most dangerous and costly mistakes are made. Learn more about Cureatr at cureatr.com.

    SinfoníaRx is a leading provider of medication therapy management (MTM) services. Through its comprehensive suite of innovative healthcare solutions, SinfoníaRx provides direct support to health plans, health systems, provider organizations, and pharmacies.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/medication-management-services-leader-cureatr-acquires-sinfoniarx-301762312.html

    SOURCE Cureatr

    Get the next $TRHC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRHC

    DatePrice TargetRatingAnalyst
    5/10/2023$7.00 → $10.00Market Perform → Outperform
    SVB Securities
    3/2/2022$30.00 → $15.00Buy
    Benchmark
    2/28/2022$23.00 → $11.00Market Perform
    SVB Leerink
    2/1/2022$24.00 → $11.00Outperform → Neutral
    Robert W. Baird
    2/1/2022$24.00 → $11.00Outperform → Neutral
    Baird
    12/2/2021$13.00Hold
    Jefferies
    11/8/2021$70.00 → $23.00Outperform
    RBC Capital
    11/8/2021$40.00 → $23.00Market Perform
    SVB Leerink
    More analyst ratings

    $TRHC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lifshitz Law PLLC Announces Investigations of VRTV, FRGI, TRHC, and SOVO

      NEW YORK, Aug. 12, 2023 (GLOBE NEWSWIRE) -- Veritiv Corporation (NYSE:VRTV) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of VRTV to an affiliate of Clayton, Dubilier & Rice, LCC for $170.00 per share in cash for each share of VRTV common stock owned. If you are a VRTV investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Fiesta Restaurant Group, Inc. (NASDAQ:FRGI) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary dutie

      8/12/23 8:17:00 PM ET
      $FRGI
      $SOVO
      $TRHC
      $VRTV
      Restaurants
      Consumer Discretionary
      Packaged Foods
      Consumer Staples
    • Tabula Rasa HealthCare Reports Second Quarter 2023 Financial Results

      Continued Strong Organic Revenue Growth of 24% Second Quarter Adjusted EBITDA of $6.3 Million Increased More Than 3x Compared to Second Quarter 2022 MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today reported financial results for the second quarter ended June 30, 2023. Highlights from the second quarter ended June 30, 2023 include: Second quarter revenue from continuing operations of $90.0 million

      8/7/23 7:02:00 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Tabula Rasa and ExactCare to Combine to Create a Leading, Independent Pharmacy Care Management Company That Services Patients with the Most Complex Needs

      $10.50 Per Share All-Cash Transaction Represents a Significant Premium for Tabula Rasa Stockholders Combination of Two Highly Complementary Companies to Benefit Patients, Providers and Payers with First of its Kind Risk Management Platform in Pharmacy Care Expands the Reach of Tabula Rasa's MedWise Technology Platform to Multiple Provider and Payer Markets MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® ("TRHC," "Tabula Rasa" or the "Company") (NASDAQ:TRHC), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today announced it has entered into a definitive agreement (the "Agreement") to be acquired by Nauti

      8/7/23 7:00:00 AM ET
      $TRHC
      Business Services
      Consumer Discretionary

    $TRHC
    SEC Filings

    See more
    • SEC Form EFFECT filed by Tabula Rasa HealthCare Inc.

      EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)

      11/17/23 12:15:07 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Tabula Rasa HealthCare Inc.

      EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)

      11/17/23 12:15:26 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Tabula Rasa HealthCare Inc.

      EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)

      11/17/23 12:15:13 AM ET
      $TRHC
      Business Services
      Consumer Discretionary

    $TRHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Tabula Rasa HealthCare upgraded by SVB Securities with a new price target

      SVB Securities upgraded Tabula Rasa HealthCare from Market Perform to Outperform and set a new price target of $10.00 from $7.00 previously

      5/10/23 6:30:40 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Benchmark reiterated coverage on Tabula Rasa HealthCare with a new price target

      Benchmark reiterated coverage of Tabula Rasa HealthCare with a rating of Buy and set a new price target of $15.00 from $30.00 previously

      3/2/22 7:40:57 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • SVB Leerink reiterated coverage on Tabula Rasa HealthCare with a new price target

      SVB Leerink reiterated coverage of Tabula Rasa HealthCare with a rating of Market Perform and set a new price target of $11.00 from $23.00 previously

      2/28/22 4:58:06 AM ET
      $TRHC
      Business Services
      Consumer Discretionary

    $TRHC
    Financials

    Live finance-specific insights

    See more
    • Tabula Rasa HealthCare Reports Second Quarter 2023 Financial Results

      Continued Strong Organic Revenue Growth of 24% Second Quarter Adjusted EBITDA of $6.3 Million Increased More Than 3x Compared to Second Quarter 2022 MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today reported financial results for the second quarter ended June 30, 2023. Highlights from the second quarter ended June 30, 2023 include: Second quarter revenue from continuing operations of $90.0 million

      8/7/23 7:02:00 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Tabula Rasa HealthCare Schedules Second Quarter 2023 Earnings Conference Call

      MOORESTOWN, N.J., July 25, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its second quarter 2023 financial results Tuesday, August 8, 2023 at 8:30 a.m. EDT. The Company's financial results for the second quarter 2023 ended June 30, 2023, will be released after the close of the market Monday, August 7, 2023. Those interested in participating via webcast in listen-only mode can access the event here. For participants who would like to participate via telephone, please register here to receive the dial-in numbe

      7/25/23 4:30:00 PM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Tabula Rasa HealthCare Reports First Quarter 2023 Financial Results

      First Quarter Results Show Benefits of Consistent Execution on Financial and Strategic Objectives First Quarter Revenue Growth of 32% Compared to First Quarter 2022 Raises Full Year 2023 Revenue and Adjusted EBITDA Guidance MOORESTOWN, N.J., May 8, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the first quarter ended March 31, 2023. Highlights from the first quarter ended March 31, 2023, include: First quarter revenu

      5/8/23 4:30:00 PM ET
      $TRHC
      Business Services
      Consumer Discretionary

    $TRHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mitchell Ronald Paul returned 79,332 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)

      11/14/23 9:09:01 PM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Purcell Michael J. returned 139,322 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)

      11/14/23 9:02:19 PM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Schwartz Jonathan David returned 78,388 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)

      11/14/23 8:59:36 PM ET
      $TRHC
      Business Services
      Consumer Discretionary

    $TRHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Tabula Rasa HealthCare Inc. (Amendment)

      SC 13D/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)

      8/8/23 4:01:33 PM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Tabula Rasa HealthCare Inc. (Amendment)

      SC 13G/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)

      2/9/23 11:35:13 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Tabula Rasa HealthCare Inc. (Amendment)

      SC 13D/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)

      9/14/22 3:21:21 PM ET
      $TRHC
      Business Services
      Consumer Discretionary

    $TRHC
    Leadership Updates

    Live Leadership Updates

    See more
    • Tabula Rasa HealthCare Provides Corporate Updates

      Appoints Brian Adams as President and Chief Executive Officer and a Member of the Board of Directors, Effective Immediately Appoints Richard W. Rew II as Chief Legal Officer and Corporate Secretary Announces Preliminary Unaudited First Quarter 2023 Revenue Exceeding Guidance MOORESTOWN, N.J., April 13, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today announced the appointment of Brian Adams as President and Chief Executive Officer. Mr. Adams, who was serving as TRHC's interim Chief Executive Officer since September 2022 and previously served as the Company's Co-Pre

      4/13/23 4:05:00 PM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Tabula Rasa HealthCare Names April Gill Chief Commercial Officer

      MOORESTOWN, N.J., Nov. 1, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today announced the appointment of April D. Gill as Chief Commercial Officer. Ms. Gill has more than 20 years of experience in healthcare with a proven track record exceeding client satisfaction, sales, and profitability goals. In this newly created role, Ms. Gill will oversee development and execution of TRHC's commercialization with broad responsibility for strategy, product, marketing, communication

      11/1/22 8:30:00 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Tabula Rasa HealthCare Announces Leadership Transition

      Drs. Calvin H. Knowlton and Orsula V. Knowlton to retire from the Company Co-President Brian Adams Named Interim CEO Director Michael Purcell Named Independent Board Chairman MOORESTOWN, N.J., Sept. 14, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today announced that co-founders Dr. Calvin H. Knowlton, BScPharm, MDiv, PhD, ScD (hon), Chief Executive Officer and Board Chairman, and Dr. Orsula V. Knowlton, PharmD, MBA, Co-President and Chief Marketing and New Business Development Officer, will retire from TRHC and step down as members of the Board of Directors, effective immediately. Dir

      9/14/22 8:00:00 AM ET
      $TRHC
      Business Services
      Consumer Discretionary